Trastuzumab and Biosimilars
About Trastuzumab [HER2+ antibody]
Trastuzumab blocks the activity of HER2 and triggers a type of immune reaction that kills cells that have a lot of HER2. It is a type of targeted therapy drug called a monoclonal antibody.
Trastuzumab is approved to be used alone or with other drugs to treat:
- Breast cancer that is HER2 positive (HER2+).
- Stomach adenocarcinoma or gastroesophageal junction adenocarcinoma that has metastasized.
Commercial Products
| Attributes | RD code | Brand Name | Approved | Owner | Area | WebSite |
|---|---|---|---|---|---|---|
| Originator | J9355 | Herceptin® | 1998 | Roche | USA | roche.com |
| Biosimilar | HLX02 | CNN:汉曲优® | 2020 | Henlius (CNN:复宏汉霖) | China | henlius.com |
| Biosimilar | HS022 | CNN:安瑞泽® | 2023 | BioRay(CNN:博锐生物>海正生物>贝达药业) | China | bioraypharm.com |
| Biosimilar | TQ-B211 | CNN:赛妥® | 2023 | CHIATHAI TIANQIONG(CNN:正大天晴药业) | China | cttq.com |
| Biosimilar | AK-HER2 | CNN:安赛汀® | 2023 | AnKeBio(CNN:安科生物) | China | ankebio.com |
| Biosimilar | QL1701 | CNN:安曲妥 | 2024 | QiLu Pharma(CNN:齐鲁制药) | China | qilu-pharma.com |
Business Cooperation
- You wish to purchase this product (Trastuzumab).
- Do you want to obtain the distribution rights for this product (Trastuzumab)?